Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Assets (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Current Assets for 4 consecutive years, with $324.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 128.42% to $324.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $324.6 million through Dec 2025, up 128.42% year-over-year, with the annual reading at $324.6 million for FY2025, 128.42% up from the prior year.
  • Current Assets hit $324.6 million in Q4 2025 for Taysha Gene Therapies, up from $300.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $324.6 million in Q4 2025 to a low of $43.0 million in Q3 2022.
  • Historically, Current Assets has averaged $152.9 million across 4 years, with a median of $136.4 million in 2024.
  • Biggest YoY gain for Current Assets was 299.53% in 2023; the steepest drop was 32.31% in 2023.
  • Year by year, Current Assets stood at $96.4 million in 2022, then skyrocketed by 55.44% to $149.9 million in 2023, then dropped by 5.16% to $142.1 million in 2024, then skyrocketed by 128.42% to $324.6 million in 2025.
  • Business Quant data shows Current Assets for TSHA at $324.6 million in Q4 2025, $300.0 million in Q3 2025, and $316.3 million in Q2 2025.